Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease
Lu L, Pichet Binette A, Hristovska I, Janelidze S, Smets B, Cumplido-Mayoral I, Vasanthakumar A, Milkovich B, Global Neurodegeneration Proteomics Consortium (GNPC), An L, Ossenkoppele R, Krish V, et al.. Nature Aging, 2026-05-15
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The APOE locus is the strongest genetic factor for Alzheimer's disease, with ε4 increasing and ε2 decreasing risk, yet the basis of these opposing effects remains unclear. Here we performed a multicohort proteomic analysis across plasma and cerebrospinal fluid in GNPC, BioFINDER-2, ADNI, UK BioBank, and PPMI. APOE-associated protein alterations are detectable before amyloid pathology and remain stable across age and disease progression. APOE2-associated proteins were enriched in pathways related to cellular maintenance and anti-inflammatory processes. By contrast, APOE4 showed a limited set of upstream mediators linked to cell-cycle and oligodendrocyte precursor cell biology, and a broader group of proteins reflecting vascular, immune, and proteostatic dysfunction shaped by downstream pathology. Comparative analyses highlighted allele-specific mediators and oppositely regulated proteins contributing to differential disease risk. Together, these findings reveal that APOE2 and APOE4 shape Alzheimer's disease risk through distinct molecular architectures and identify candidate biomarkers and targets for allele-specific interventions.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study. This proteomic study found that APOE ε2 and ε4 appear to affect Alzheimer's risk through different molecular pathways. It identifies candidate biomarkers and targets for allele-specific interventions, but no treatment is tested.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lu, L., Pichet Binette, A., Hristovska, I., Janelidze, S., Smets, B., Cumplido-Mayoral, I., et al. (2026). Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease. Nature Aging. https://doi.org/10.1038/s43587-026-01123-0
Vancouver
Lu L, Pichet Binette A, Hristovska I, Janelidze S, Smets B, Cumplido-Mayoral I, et al. Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease. Nature Aging. 2026. doi:10.1038/s43587-026-01123-0. PMID: 42141098.
BibTeX
@article{lu2026-42141098,
author = {Lu, L. and Pichet Binette, A. and Hristovska, I. and Janelidze, S. and Smets, B. and Cumplido-Mayoral, I. and Vasanthakumar, A. and Milkovich, B. and An, L. and Ossenkoppele, R. and Krish, V. and others},
title = {{Proteomic signatures of the APOE ε4 and APOE ε2 genetic variants and Alzheimer's disease}},
journal = {Nature Aging},
year = {2026},
doi = {10.1038/s43587-026-01123-0},
pmid = {42141098},
url = {https://doi.org/10.1038/s43587-026-01123-0}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Together, these findings reveal that APOE2 and APOE4 shape Alzheimer's disease risk through distinct molecular architectures and identify candidate biomarkers and targets for allele-specific interventions.
Why it matters
This proteomic study found that APOE ε2 and ε4 appear to affect Alzheimer's risk through different molecular pathways. It identifies candidate biomarkers and targets for allele-specific interventions, but no treatment is tested.
New to this subject? Start with our plain-English guide: Genetics →
Study details
- Study designcohort
- Evidence strengthModerate
Limitations
Cohort heterogeneity complicates interpretation: GNPC lacked AD biomarkers to confirm diagnoses (findings were validated in biomarker-confirmed BioFINDER-2), UK Biobank was mostly younger and unimpaired, and PPMI is Parkinson's-focused; mediation analyses were cross-sectional and statistical rather than causal; and AD diagnosis and amyloid status were mostly modelled as binary variables.
How this study scored 56/100
Published in a leading specialty journal, and it is a cohort study following people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 55 of the 98 points we could judge it on, which is 56 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Aging) |
| Journal's citation record | 1 / 4 | Nature Aging: journal h-index 103 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A cohort study following people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 6 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 3.0 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 5 / 6 | Cited 24.8× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 6 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Niklas Mattsson: h-index 109 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Lund University: institution h-index 1,119 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 10 institution(s) in 4 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42141098) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 55 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 55 of the 98 points we could judge it on is 56 out of 100. |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Genetics from nearby years
Also tagged “precursor”
1,337 studies in the library carry the topic tag “precursor”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,337 tagged studies.